Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum91473ArticlesСтатьиResearch ArticleIdiopaticheskiy fibroziruyushchiy al'veolit: sovremennye podkhody k diagnostike i terapiiИдиопатический фиброзирующий альвеолит: современные подходы к диагностике и терапииAvdeevaO. EАвдееваО. ЕAvdeevS. NАвдеевС. ННИИ пульмонологии Минздрава РФ1504200244VOL 4, NO4 (2002)ТОМ 4, №4 (2002)19520228122021Copyright ©; 2002, Consilium MedicumCopyright ©; 2002, ООО "Консилиум Медикум"2002Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/91473

Идиопатический фиброзирующий альвеолит (ИФА) является одним из наиболее часто встречающихся и, в то же время, плохо изученных заболеваний из группы интерстициальных заболеваний легких (ИЗЛ). ИФА характеризуется воспалением и фиброзом легочного интерстиция и воздухоносных пространств, дезорганизацией структурно-функциональных единиц паренхимы (Scadding, 1964), что приводит к развитию рестриктивных изменений легких, нарушению газообмена, прогрессирующей дыхательной недостаточности и в конечном итоге к гибели больного. Современная терапия ИФА построена в основном на противовоспалительной терапии (кортикостероиды и цитостатики), т.е. препаратах, способных воздействовать на воспалительные и иммунологические звенья развития заболевания.

Scadding J.G. Fibrosing alveolitis. BMJ 1964; II: 686.Hamman L, Rich A.R. Fulminanting diffuse interstitial fibrosis of the lung. Trans Am Clin Climatol Assoc 1935; 51: 154-63.Olson J, Colby T.V, Elliott C.G. Hamman-Rich syndrome revisited. Mayo Clin Proc 1990; 65: 1538-48.Scadding J.G. Diffuse interstitial fibrosis of the lung. BMJ 1960; 1: 443-0.Rindfleisch G.E. Ueber Cirrhosis Cystica Pulmonum. Zentralbl Pathol 1897; 8: 864-5.British Thoracic Society recommendatons. 1999. The diagnosis, assessment and treatment of diffuse parenchymal disease in adults. Thorax 54 (Suppl. 1): S1-S30.International Consensus Statement. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and European Respiratory Society. Am J Respir Crit Care Med 2000; 161: 646-64.Costabel U, King T.E. International Consensus Statement on idiopathic pulmonary fibrosis: Eur Respir J 2001; 17: 163-7.Kitaichi M. Pathologic features and the classification of interstitial pneumonias of unknown etiology. Bul. Chest Dis Res Inst Kyoto Univ 1990; 23: 1-18.Liebow A.A, Carrington C.B. The interstitial pneumonias. In: M.Simon, E.J.Potchen and M.Lemay, eds. Frontiers of pulmonary radiology,1 ed. Grune and Stratton, New York 1969; 102-41.Katzenstein A.L.A, Askin F.B. Surgical pathology of non - neoplastic diseases. WB.Saunders, Philadelphia 1997.Muller N.C, Colby T.V. Idiopathic interstitial pneumonias: high - resolution CT and histologic findings. Radiographics 1997; 17: 1016-22.Katzenstein A.L, Fiorelli R.F. Nonspecific interstitial pneumonia/fibrosis: histologic features and clinical significance. Am J Surg Pathol 1994; 18: 136-47.Katzenstein A.L.A, Myers J.L, Mazur M.T. Acute interstitial pneumonia: a clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 1986; 10: 256-67.Yousem S.A, Colby T.V, Gaensler E.A. Respiratory bronchiolitis - associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc 1989; 64: 1373-80.Corrin B. Pathology of interstitial lung disease.Semin. Resp Crit Care Med 1994; 15: 61-76.Demedts M, Wells A.U, Anto J.M, Costabel U, Hubbard R, Cullinan P, Slabbynck H, Rizzato G, Poletti V, Verbeken E.K, Thomeer M.J, Kokkarinen J, Dalphin J.C, Newman Taylor A. Interstitial lung diseases: an epidemiological overview. Eur Respir J 2001; 18 (Suppl. 32): 2-16.Coultas D.B, Zumwalt R.E, Black W.C, Sobonya R.E. The epidemiology of interstitial lung disease. Am J Respir Crit Care Med 1994; 150: 967-72.Scott J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A case - control study of environmental exposure to dust. Br Med J 1990; 301: 1015-7.Baumgartner K.B, Samet J, Stidley C.A, Colby T.V, Waldron J.A, and the Collaborating Centers. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155: 242-8.Hubbard R, Johnston I.D.A, Coultas D, Britton J. Mortality rates from cryptogenic fibrosing alveolitis is seven countries. Thorax 1996; 51: 711-6.Tobin R.W, Pope C.E II, Pellefrini C.A, Emond M.J, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999; 158: 1804-8.Lympany P.A, du Bois R.M. Interstitial lung disease: basic mechanisms and genetic predisposition. Monaldi Arch Chest Dis 1997; 52: 33-6.Utz J.P, Ryu J.H, Douglas W.W, Hartman T.E, Tazelaar H.D, Myers J.L, Allen M.S, Schroeder D.R.. High short - term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 2001; 17: 175-9.Raghu G, Mageto Y.N, Lockhart D, Schmidt R.A, Wood D.E, Godwin J.D. 1998. The accuracy of the clinical diagnosis of new - onset idiopathic pulmonary fibrosis and other interstitial lung disease. A prospective study. Chest 1999; 116: 1168-74.Flaherty K.R, Toews G.B, Travis W.D, Colby T.V, Kazerooni E.A, Gross B.H, Jain A, Strawderman III R.L, Paine R, Flint A, Lynch III J.P, Martinez F.J. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002; 19: 275-83.Johnston I.D.A, Prescott R.J, Chalmers J.C, Rudd R.M, and for the Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. 1997. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 52: 38-44.Egan J.J, Woodcock A.A, Stewart J.P. Viruses and idiopathic pulmonary fibrosis. Eur Respir J 1997; 10: 1433-7.du Bois R.M, Wells A.U. Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur Respir J 2001; 18 (Suppl. 32): 43s-55s..Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis: a population - based cohort study. Am J Respir Crit Care Med 2000; 161: 5-8.Piirila P, Sovijarvi A.R.A. Crackles: recording, analysis and clinical significance. Eur Respir J 1995; 8: 2139-48.Crystal R.G, Bitterman P.B, Rennard S.I, Hance A.J, Keogh B.A. Interstitial lung diseases of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1984; 310: 154-66, 235-44.Honda Y, Kuroki Y, Matsuura E. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152: 1860-6.Kohno N, Awaya Y, Oyama T. et al. KL-6, a mucin - like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993; 148: 637-42.Авдеева О.Е., Лебедин Ю.С., Авдеев С.Н., Чуканов С., Черняк А.В., Самсонова М.В., Чучалин А.Г. Гликозилированный муцин - антиген 3EG5- сывороточный маркер активности и тяжести при интерстициальных заболеваниях легких. Пульмонология. 1998; 2: 22-7.Schwartz D.A, Van Fossen D.S, Davis C.S, Helmers R.A, Dayton C.S, Burmeister L.F, Hunninkhake G.W. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149: 444-9.Wells A.U, King A.D, Rubens M.B, Cramer D, du Bois R.M, Hansell D.M. Lone cryptogenic fibrosing alveolitis: A functional - morphologic correlation based on extent of disease on thin - section computed tomography. Am J Respir Crit Care Med 1997; 155: 1367-75.King T.E.Jr. Diagnostic advances in idiopathic pulmonary fibrosis. Chest 1991; 100: 238-41.Agusti A.G.N, Roca J, Gea J, Wagner P.D, Xaubet A, Rodriguez-Roisin R. Mechanisms of gas - exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991; 143: 219-25.Orens J.B, Kazerooni E.A, Martinez F.J, Curtis J.L, Gross B.H, Flint A, Lynch III J.P. The sensitivity of high - resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy: a prospective study. Chest 1995; 108: 109-15.Padley S.P, Padhani A.R, Nicholson A, Hansell D.M. Pulmonary sarcoidosis mimicking cryptogenic fibrosing alveolitis on CT. Clin Radiol 1996; 51: 807-10.Tung K.T, Wells A.U, Rubens M.B, Kirk J.M, du Bois R.M, Hansell D.M. Accuracy of the typical computed tomographic appearances of fibrosing alveolitis. Thorax 1993; 48: 334-8.Wells A.U, Hansell D.M, Rubens M.B, Cullinan P, Black C.M, du Bois R.M. The predictive value of appearances on thin - section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993; 148: 1076-82.Wells A.U, Rubens M.B, du Bois R.M, Hansell D.M. Functional impairment in fibrosing alveolitis: relationship to reversible disease on thin section computed tomography. Eur Respir J 1997; 10: 280-5.Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990; 84: 365-9.Drent M, van Nierop M.A, Gerritsen F.A, Wouters E.F, Mulder P.G. A computer program using BALF-analysis results as a diagnostic tool in interstitial lung. Am J Respir Crit Care Med 1996; 153 (2): 736-41.Boomars K.A, Wagenaar S.S, Mulder P.G.H, van Velzen-Blad H, van den Bosch J.M.M. Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis. Thorax 1995; 50: 1087-92.Haslam P.L, Turton C.W.G, Heard B, Lukoszek A, Collins J.V, Salsbury A.J, Turner-Warwick M. Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features. Thorax 1980; 35: 9-18.Raghu G. Interstitial lung disease: a diagnostic approach: are CT scan and lung biopsy indicated in every patient? Am J Respir Crit Care Med 1995; 151: 909-14.Bensard D.D, Mc Intyre Jr.R.C, Waring B.J, Simon J.S. Comparison of video thoracoscopic lung biopsy to open lung biopsy in the diagnosis of interstitial lung disease. Chest 1993; 103: 765-70.Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population - based cohort study. Chest 1998; 113: 396-400.Gay S.E, Kazerooni E.A, Toews G.B, Lynch III J, Gross B.H, Cascade P.N, Spizarny D.L, Flint A, Schork M.A, Whyte R.I, Popovich J, Hyzy R, Martinez F.J. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157: 1063-72.Panos R.J, Mortenson R, Niccoli S.A, King Jr.T.E. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88: 396-404.Silverman J.J, Talbot T.J. Diffuse interstitial pulmonary fibrosis camouflated by hypermetabolism and cardiac failure: antemortem diagnosis with biopsy and cateterization studies. Ann Intern Med 1953; 38: 1326-38.Selman M, Carrillo G, Salas J, Padilla R.P, Perez-Chavira R, Sansores R, Chapela R. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 1998; 114: 507-12.Lynch J.P, Mc Cune W.J. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Crit Care Med 1997; 155: 395-420.Raghu G, Depaso W.J, Cain K, Hammar S.P, Wetzel C.E, Dreis D.F, Hutchinson J, Pardee N.E, Winterbauer R.H. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double - blind randomized, placebo - controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-6.Johnson M.A, Kwan S, Snell N.J.C, Nunn A.J, Darbyshire J.H, Turner-Warwick M. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44: 280-8.Mason R.J, Schwarz M.I, Hunninghake G.W, Musson R.A. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future. Am J Respir Crit Care Med 1999; 160: 1771-7.Douglas W.W, Ryu J.H, Swensen S.J, Offord K.P, Schroeder D.R, Caron G.M, De Remee R.A, Members, and of the Lung Study Group. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis: a randomized prospective study. Am J Respir Crit Care Med 1998; 158: 220-5.du Bois R.M. Interferon Gamma-1b for the treatment of idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1302-4.Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L.H. A preliminary study of long - term treatment with interferon Gamma-1b and low - dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341: 1264-9.Raghu G, Johnson W.C, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open - label Phase II study. Am J Respir Crit Care Med 1999; 159: 1061-9.Mac Nee W, Rahman I. Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax 1995; 50 (Suppl. 1): S53-S58.Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high - dose N-acetylcysteine in fibrosing alveolitis: adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156: 1897-901.Harris-Eze A.O, Sridhar G, Clemens R.E, Gallagher C.G, Marciniuk D.D. Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med 1994; 150: 1616-22.Freudenberger T, Raghu G. Iidiopathic pulmonary fibrosis: an evolving approach to diagnosis and treatment. Eur Respir Mon 2000; 14: 79-95.